Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α.

Keppeke GD, Nunes E, Ferraz ML, Silva EA, Granato C, Chan EK, Andrade LE.

PLoS One. 2012;7(9):e45392. doi: 10.1371/journal.pone.0045392. Epub 2012 Sep 24.

2.

Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.

Stinton LM, Myers RP, Coffin CS, Fritzler MJ.

BMC Gastroenterol. 2013 Mar 19;13:50. doi: 10.1186/1471-230X-13-50.

3.

Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.

Keppeke GD, Calise SJ, Chan EK, Andrade LE.

World J Gastroenterol. 2016 Feb 14;22(6):1966-74. doi: 10.3748/wjg.v22.i6.1966. Review.

4.

Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.

Covini G, Carcamo WC, Bredi E, von Mühlen CA, Colombo M, Chan EK.

Antivir Ther. 2012;17(5):805-11. doi: 10.3851/IMP1993. Epub 2011 Dec 1.

PMID:
22293655
5.

Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.

Keppeke GD, Satoh M, Ferraz ML, Chan EK, Andrade LE.

Immunol Res. 2014 Oct;60(1):38-49. doi: 10.1007/s12026-014-8515-2.

PMID:
24845459
6.

Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients.

Carcamo WC, Ceribelli A, Calise SJ, Krueger C, Liu C, Daves M, Villalta D, Bizzaro N, Satoh M, Chan EK.

J Clin Immunol. 2013 Feb;33(2):420-6. doi: 10.1007/s10875-012-9827-4. Epub 2012 Oct 26.

PMID:
23100146
7.

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.

Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, Poynard T, Katlama C, Pialoux G, Bréchot C, Pol S.

Gut. 2000 Nov;47(5):694-7.

8.

Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.

Muratori P, Muratori L, Guidi M, Granito A, Susca M, Lenzi M, Bianchi FB.

Clin Infect Dis. 2005 Feb 15;40(4):501-7. Epub 2005 Jan 21.

PMID:
15712070
9.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

10.

Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients.

Novembrino C, Aghemo A, Ferraris Fusarini C, Maiavacca R, Matinato C, Lunghi G, Torresani E, Ronchi M, Garlaschi MC, Ramondetta M, Colombo M.

J Viral Hepat. 2014 Dec;21(12):944-9. doi: 10.1111/jvh.12281. Epub 2014 Jul 14.

PMID:
25040504
11.

[Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients].

Li YX, Yang YJ, Yang M, Chen LY, Lu JJ, Ma YJ, Liu K, Lei XZ, Tang H.

Zhonghua Gan Zang Bing Za Zhi. 2013 May;21(5):345-7. doi: 10.3760/cma.j.issn.1007-3418.2013.05.008. Chinese.

PMID:
24025134
12.

Differential capacity of therapeutic drugs to induce Rods/Rings structures in vitro and in vivo and generation of anti-Rods/Rings autoantibodies.

Keppeke GD, Prado MS, Nunes E, Perazzio SF, Rodrigues SH, Ferraz ML, Chan EK, Andrade LE.

Clin Immunol. 2016 Dec;173:149-156. doi: 10.1016/j.clim.2016.10.004. Epub 2016 Oct 13.

PMID:
27746381
13.

Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.

Lunel F, Veillon P, Fouchard-Hubert I, Loustaud-Ratti V, Abergel A, Silvain C, Rifflet H, Blanchi A, Causse X, Bacq Y, Payan C; Fontevraud Study Group.

J Hepatol. 2003 Nov;39(5):826-33.

PMID:
14568267
14.

High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.

Wartelle-Bladou C, Arpurt JP, Renou C, Pariente A, Pillon D, Nalet B, Picon M, Glibert A, Chousterman M, Grasset D, Morin T, Bernard P, Fischer D, Ramdani M, Lagier E, Rotily M; Viral Hepatitis Group of the ANGH.

Gastroenterol Clin Biol. 2006 Apr;30(4):525-32.

15.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
16.

Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial.

Berg T, Hoffmann RM, Teuber G, Leifeld L, Lafrenz M, Baumgarten R, Spengler U, Zeuzem S, Pape GR, Hopf U.

Liver. 2000 Dec;20(6):427-36.

PMID:
11169056
17.

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.

Bell H, Hellum K, Harthug S, Myrvang B, Ritland S, Maeland A, von der Lippe B, Bjøro K, Skaug K, Gutigard BG, Raknerud N, Simmonds P.

Scand J Gastroenterol. 1999 Feb;34(2):194-8.

PMID:
10192200
18.

Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.

Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, Myers RP, Leger JM, Servan J, Piette JC.

Arthritis Rheum. 2002 Dec;46(12):3317-26.

19.
20.

Supplemental Content

Support Center